StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > On the way down to $1

<< Previous

Bullboard Posts

Next >>

Comment by Stockish12on Mar 03, 2021 3:55pm

127 Views

Post# 32707584

RE:RE:RE:RE:On the way down to $1

Are we there yet?

I need these two clowns on my thread to really sh*t themselves literarily.

Were you here when this dipped from $1.40 to $0.59?

You don't know the type of CEO you have here.

Do not hold your breath on this one. It would not shock me if Tripp comes around again to say Aristotle launch date postponed. He has pushed this forward many times before. It would not be anything knew if he did.

17 more trading days to the end of Q1 right? Tick Tock

<< Previous

Bullboard Posts

Next >>

AtkinsRéalis adds up to £90M in U.K.-based revenue